« Progression of Geographic Atrophy and Impact of Fundus Autofluorescence Patterns in Age-related Macular Degeneration | Main | Statin use associated with myasthenia gravis »
February 26, 2007
Good preliminary results for myopic macular degeneration treatment
INDUSTRY NEWS
OXiGENE reports that all participants in its Phase II Combretastatin A4 Phosphate trial maintained visual acuity; defined as less than a three line loss in visual acuity at three months. No serious drug-related adverse events were reported.
Posted by kjalali at February 26, 2007 06:22 AM